Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Research
You have accessRestricted Access

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

Flavio Vincenti, Gilles Blancho, Antoine Durrbach, Peter Friend, Josep Grinyo, Philip F. Halloran, Jurgen Klempnauer, Philippe Lang, Christian P. Larsen, Ferdinand Mühlbacher, Björn Nashan, Jean-Paul Soulillou, Yves Vanrenterghem, Thomas Wekerle, Mamta Agarwal, Sheila Gujrathi, Jinshan Shen, Rebecca Shi, Robert Townsend and Bernard Charpentier
JASN September 2010, 21 (9) 1587-1596; DOI: https://doi.org/10.1681/ASN.2009111109
Flavio Vincenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Blancho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Durrbach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Friend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josep Grinyo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip F. Halloran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jurgen Klempnauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Lang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian P. Larsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferdinand Mühlbacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Björn Nashan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Paul Soulillou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Vanrenterghem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Wekerle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mamta Agarwal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheila Gujrathi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinshan Shen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Shi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Townsend
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Charpentier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Belatacept is a first-in-class co-stimulation blocker in development for primary maintenance immunosuppression. A Phase II study comparing belatacept with cyclosporine (CsA) for prevention of acute rejection and protection of renal function in kidney transplant recipients demonstrated similar efficacy and significantly higher measured GFR at 1 year for belatacept, but the incidence of posttransplantation lymphoproliferative disorder was higher. Here, we present the results for the extension of this trial, which aimed to assess long-term safety and efficacy of belatacept. Seventy-eight of 102 patients who were receiving belatacept and the 16 of 26 who were receiving CsA completed the long-term extension period. GFR remained stable in patients who were receiving belatacept for 5 years, and the incidences of death/graft loss or acute rejection were low. The frequencies of serious infections were 16% for belatacept and 27% for CsA, and neoplasms occurred in 12% of each group. No patients who were treated with belatacept and one patient who was treated with CsA developed posttransplantation lymphoproliferative disorder during the follow-up period. Serious gastrointestinal disorders occurred more frequently with belatacept (12% belatacept versus 8% CsA), and serious cardiac disorders occurred more frequently with CsA (2% belatacept versus 12% CsA). Pharmacokinetic analyses showed consistent exposure to belatacept over time. CD86 receptor saturation was higher in patients who were receiving belatacept every 4 weeks (74%) compared with every 8 weeks (56%). In conclusion, this study demonstrated high patient persistence with intravenous belatacept, stable renal function, predictable pharmacokinetics, and good safety with belatacept over 5 years.

Footnotes

  • Copyright © 2010 by the American Society of Nephrology
View Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 21 (9)
Journal of the American Society of Nephrology
Vol. 21, Issue 9
1 Sep 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Flavio Vincenti, Gilles Blancho, Antoine Durrbach, Peter Friend, Josep Grinyo, Philip F. Halloran, Jurgen Klempnauer, Philippe Lang, Christian P. Larsen, Ferdinand Mühlbacher, Björn Nashan, Jean-Paul Soulillou, Yves Vanrenterghem, Thomas Wekerle, Mamta Agarwal, Sheila Gujrathi, Jinshan Shen, Rebecca Shi, Robert Townsend, Bernard Charpentier
JASN Sep 2010, 21 (9) 1587-1596; DOI: 10.1681/ASN.2009111109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Five-Year Safety and Efficacy of Belatacept in Renal Transplantation
Flavio Vincenti, Gilles Blancho, Antoine Durrbach, Peter Friend, Josep Grinyo, Philip F. Halloran, Jurgen Klempnauer, Philippe Lang, Christian P. Larsen, Ferdinand Mühlbacher, Björn Nashan, Jean-Paul Soulillou, Yves Vanrenterghem, Thomas Wekerle, Mamta Agarwal, Sheila Gujrathi, Jinshan Shen, Rebecca Shi, Robert Townsend, Bernard Charpentier
JASN Sep 2010, 21 (9) 1587-1596; DOI: 10.1681/ASN.2009111109
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Sources of Variation in the Carbon Footprint of Hemodialysis Treatment
  • The Relationship between Cerebrovascular Reactivity and Cerebral Oxygenation During Hemodialysis
  • Hypomagnesemia, Hypocalcemia, and Tubulointerstitial Nephropathy Caused by Claudin-16 Autoantibodies
Show more Clinical Research

Cited By...

  • Post-Transplant Cardiovascular Disease
  • First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28
  • Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients
  • Haptoglobin Enhances Cardiac Transplant Rejection
  • Candida-Elicited Murine Th17 Cells Express High CTLA-4 Compared with Th1 Cells and Are Resistant to Costimulation Blockade
  • 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses
  • Calcineurin Inhibitors: 40 Years Later, Can't Live Without ...
  • Risk of posttransplant lymphoproliferative disorder associated with use of belatacept
  • Current trends in immunosuppressive therapies for renal transplant recipients
  • Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire